Herpes simplex virus type 1 amplicon vectors for the infectious delivery and expression of genomic DNA loci

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 4, 2005, Pages 337-345

  Senior, Steven L ^a   Wade Martins, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bacterial artificial chromosome; Functional genomics; Gene therapy; Gene transfer; Genomic DNA; Herpes simplex virus 1 amplicon

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CYCLIN DEPENDENT KINASE 2; GENOMIC DNA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LOW DENSITY LIPOPROTEIN RECEPTOR; VIRUS VECTOR;

AMPLICON; BACTERIAL ARTIFICIAL CHROMOSOME; BACTERIAL INFECTION; BACTERIOPHAGE P1 ARTIFICIAL CHROMOSOME; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE LOCUS; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; NONHUMAN; NULL CELL; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

CHROMOSOMES, ARTIFICIAL, BACTERIAL; DNA, RECOMBINANT; GENE AMPLIFICATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; TRANSGENES;

HUMAN HERPESVIRUS 1;

EID: 23344450226     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y: An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 19(11):1067-1070.
2. White RE, Wade-Martins R, James MR: Infectious delivery of 120-kilobase genomic DNA by an Epstein-Barr virus amplicon vector. Mol Ther (2002) 5(4):427-435.
3. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S: Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet (1998) 18(2):180-183.
4. Muyrers JP, Zhang Y, Testa G, Stewart AF: Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res (1999) 27(6):1555-1557.
5. Zhang Y, Muyrers JP, Testa G, Stewart AF: DNA cloning by homologous recombination in Escherichia coli. Nat Biotechnol (2000) 18(12):1314-1317.
6. Copeland NG, Jenkins NA, Court DL: Recombineering: A powerful new tool for mouse functional genomics. Nat Rev Genet (2001) 2(10):769-779.
7. Jin BK, Belloni M, Conti B, Federoff HJ, Starr R, Son JH, Baker H, Joh TH: Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum Gene Ther (1996) 7(16):2015-2024.
8. Song S, Wang Y, Bak SY, Lang P, Ullrey D, Neve RL, O'Malley KL, Geller AI: An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. J Neurochem (1997) 68(5):1792-1803.
9. Magram J, Chada K, Costantini F: Developmental regulation of a cloned adult β-globin gene in transgenic mice. Nature (1985) 315(6017):338-340.
10. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA: Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science (1994) 266(5191):1705-1708.
11. Schedl A, Ross A, Lee M, Engelkamp D, Rashbass P, van Heyningen V, Hastie ND: Influence of PAX6 gene dosage on development: Overexpression causes severe eye abnormalities. Cell (1996) 86(1):71-82.
12. Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS, Gearhart JD: Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet (1997) 6(9):1535-1541.
13. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, Heintz N: A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature (2003) 425(6961):917-925.
14. Heintz N: Gene expression nervous system atlas (GENSAT). Nat Neurosci (2004) 7(5):483.
15. Yang XW, Wynder C, Doughty ML, Heintz N: BAC-mediated gene-dosage analysis reveals a role for Zipro1 (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin. Nat Genet (1999) 22(4):327-335.
16. Heaney JD, Rettew AN, Bronson SK: Tissue-specific expression of a BAC transgene targeted to the HPRT locus in mouse embryonic stem cells. Genomics (2004) 83(6):1072-1082.
17. Zammit PS, Carvajal JJ, Golding JP, Morgan JE, Summerbell D, Zolnerciks J, Partridge TA, Rigby PW, Beauchamp JR: Myf5 expression in satellite cells and spindles in adult muscle is controlled by separate genetic elements. Dev Biol (2004) 273(2):454-465.
18. Sarsero JP, Li L, Holloway TP, Voullaire L, Gazeas S, Fowler KJ, Kirby DM, Thorburn DR, Galle A, Cheema S, Koenig M et al: Human BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic mice. Mamm Genome (2004) 15(5):370-382.
19. Spaete RR, Frenkel N: The herpes simplex virus amplicon: Analyses of cis-acting replication functions. Proc Natl Acad Sci USA (1985) 82(3):694-698.
20. Spaete RR, Frenkel N: The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector. Cell (1982) 30(1):295-304.
21. Marsh DR, Dekaban GA, Tan W, Strathdee CA, Weaver LC: Herpes simplex viral and amplicon vector-mediated gene transfer into glia and neurons in organotypic spinal cord and dorsal root ganglion cultures. Mol Ther (2000) 1(5 Pt 1):464-478.
22. Sandler VM, Wang S, Angelo K, Lo HG, Breakefield XO, Clapham DE: Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. J Neurosci Methods (2002) 121(2):211-219.
23. Agudo M, Trejo JL, Lim F, Avila J, Torres-Aleman I, Diaz-Nido J, Wandosell F: Highly efficient and specific gene transfer to Purkinje cells in vivo using a herpes simplex virus I amplicon. Hum Gene Ther (2002) 13(5):665-674.
24. Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O: Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther (1999) 10(15):2481-2494.
25. Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO, Weissleder R: In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res (2004) 64(1):273-278.
26. Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG: Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther (2001) 12(15):1867-1879.
27. Lu B, Federoff HJ, Wang Y, Goldsmith LA, Scott G: Topical application of viral vectors for epidermal gene transfer. J Invest Dermatol (1997) 108(5):803-808.
28. Derby ML, Sena-Esteves M, Breakefield XO, Corey DP: Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Hear Res (1999) 134(1-2):1-8.
29. Wang Y, Mukherjee S, Fraefel C, Breakefield XO, Allen PD: Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Hum Gene Ther (2002) 13(2):261-273.
30. Müller L, Saydam O, Saeki Y, Heid I, Fraefel C: Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol Methods (2005) 123(1):65-72.
31. Wade-Martins R, Saeki Y, Chiocca EA: Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther (2003) 7(5 Pt 1):604-612.
32. Xing W, Baylink D, Kesavan C, Mohan S: HSV-1 amplicon-mediated transfer of 128-kb BMP-2 genomic locus stimulates osteoblast differentiation in vitro. Biochem Biophys Res Commun (2004) 319(3):781-786.
33. Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: Rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 9(18):2787-2794.
34. Goss JR, Goins WF, Lacomis D, Mata M, Glorioso JC, Fink DJ. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes (2002) 51(7):2227-2232.
35. Cortes ML, Bakkenist CJ, Di Maria MV, Kastan MB, Breakefield XO: HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Ther (2003) 10(16):1321-1327.
36. Tolba KA, Bowers WJ, Hilchey SP, Halterman MW, Howard DF, Giuliano RE, Federoff HJ, Rosenblatt JD: Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood (2001) 98(2):287-295.
37. Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG: Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther (2001) 12(15):1867-1879.
38. Hocknell PK, Wiley RD, Wang X, Evans TG, Bowers WJ, Hanke T, Federoff HJ, Dewhurst S: Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol (2002) 76(11):5565-5580.
39. MartView. Sanger Institute, Cambridge, UK (2005). http://www.ensembl.org/Homo_sapiens/martview
40. Wang Y, Camp SM, Niwano M, Shen X, Bakowska JC, Breakefield XO, Allen PD: Herpes simplex virus type 1/adeno-associated virus rep+ hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J Virol (2002) 76(14):7150-7162.
41. Heister T, Heid I, Ackermann M, Fraefel C: Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J Virol (2002) 76(14):7163-7173.
42. Yates J, Warren N, Reisman D, Sugden B: A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA (1984) 81(12):3806-3810.
43. Yates JL, Warren N, Sugden B: Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 313(6005):812-815.
44. Wilson JB, Bell JL, Levine AJ: Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J (1996) 15(12):3117-3126.
45. Kang MS, Hung SC, Kieff E: Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci USA (2001) 98(26):15233-15238.
46. Wade-Martins R, White RE, Kimura H, Cook PR, James MR: Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene. Nat Biotechnol (2000) 18(12):1311-1314.
47. 1-antitrypsin in mice. Mol Ther (2001) 4(2):122-129.
48. Wang S, Vos JM: A hybrid herpes virus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol (1996) 70(12):8422-8430.
49. Banerjee S, Livanos E, Vos JM: Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. Nat Med (1995) 1(12):1303-1308.
50. Romi H, Singer O, Rapaport D, Frenkel N: Tamplicon-7, a novel T-lymphotropic vector derived from human herpesvirus 7. J Virol (1999) 73(8):7001-7007.
51. Borenstein R, Singer O, Moseri A, Frankel N: Use of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cells. J Virol (2004) 78(9):4730-4743.
52. Borst EM, Hahn G, Koszinowski UH, Messerle M: Cloning of the human cytomegalovirus genome as an infectious bacterial artificial chromosome in Escherichia coli: A new approach for construction of HCMV mutants. J Virol (1999) 73(10):8320-8329.
53. Borst EM, Messerle M: Analysis of human cytomegalovirus oriLyt sequence requirements in the context of the viral genome. J Virol (2005) 79(6):3615-3626.
54. Borst EM, Messerle M: Construction of a cytomegalovirus-based amplicon: A vector with a unique transfer capacity. Hum Gen Ther (2003) 14(10):959-970.
55. Mahmood K, Prichard MN, Duke GM, Kemble GW, Spaete RR: Human cytomegalovirus plasmid-based amplicon vector system for gene therapy. Genet Vaccines Ther (2005) 3(1):1-11.
56. Domi A, Moss B: Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci USA (2002) 99(19):12415-12420.
57. Olschowka JA, Bowers WJ, Hurley SD, Mastrangelo MA, Federoff HJ: Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol Ther (2003) 7(2):218-227.
58. Cunningham C, Davison AJ: A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology (1993) 197(1):116-124.
59. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller AI: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol (1996) 70(10):7190-7197.
60. Stavropoulos TA, Strathdee CA: An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol (1998) 72(9):7137-7143.
61. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA: Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 3(4):591-601.
62. Saeki Y, Breakefield XO, Chiocca EA: Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med (2003) 76:51-60.
63. Logvinoff C, Epstein AL: A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-IoxP recombination system to remove helper virus. Hum Gene Ther (2001) 12(2):161-167.
64. Logvinoff C, Epstein AL: Intracellular Cre-mediated deletion of the unique packaging signal carried by a herpes simplex virus type 1 recombinant and its relationship to the cleavage-packaging process. J Virol (2000) 74(18):8402-8412.
65. Logvinoff C, Epstein AL: Genetic engineering of herpes simplex virus and vector genomes carrying IoxP sites in cells expressing Cre recombinase. Virology (2000) 267(1):102-110.
66. Spencer B, Agarwala S, Miskulin M, Smith M, Brandt CR: Herpes simplex virus-mediated gene delivery to the rodent visual system. Invest Ophthalmol Vis Sci (2000) 41(6):1392-1401.
67. Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, Breakefield XO: Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther (1998) 5(6):809-819.
68. Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza R: Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther (1999) 6(10):1751-1758.
69. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 7(10):859-866.
70. International Human Genome Mapping Consortium: A physical map of the human genome. Nature (2001) 409(6822):934-941.
71. Inoue R, Moghaddam KA, Ranasinghe M, Saeki Y, Chiocca EA, Wade-Martins R: Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther (2004) 11(15):1195-1204.
72. Caskey CT, Kruh GD: The HPRT locus. Cell (1979) 16(1):1-9.
73. Brown MS, Goldstein JL: Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell (1975) 6(3):307-316.
74. Sudhof TC, Van der Westhuyzen DR, Goldstein JL, Brown MS, Russell DW: Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene. J Biol Chem (1987) 262(22):10773-10779.
75. Rader DJ: Gene therapy for familial hypercholesterolemia. Nutr Metab Cardiovasc Dis (2001) 11(Suppl 5):40-44.
76. Steele FR: Gene therapy tools for functional genomics. Genomics (2002) 80(1):1.
77. Ackermann M, Fraefel C: One giant genomic leap for gene transfer technology. Mol Ther (2003) 7(5 Pt 1):571.
78. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell (1995) 83(6):993-1000.
79. Robertson KD, Jones PA: Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene (1999) 18(26):3810-3820.
80. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol (2001) 11(2):159-168.
81. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH et al: Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 1(3):269-277.
82. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC: Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 62(19):5551-5558.
83. Wozney JM: Bone morphogenetic proteins. Prog Growth Factor Res (1989) 1(4):267-280.
84. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V: Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology (1992) 130(3):1318-1324.
85. Genome Bioinformatics. University of California, Santa Cruz, CA, USA (2005). http://www.genome.ucsc.edu/
86. BACPAC Resources Center. Children's Hospital Oakland Research Institute, Oakland, CA, USA (2005). http://bacpac.chori.org/
87. Fukazawa T, Maeda Y, Sladek FM, Owen-Schaub LB: Development of a cancer-targeted tissue-specific promoter system. Cancer Res (2004) 64(1):363-369.